Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Isavuconazole (Cresemba®) is recommended as an option for use within NHS Wales for the treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list / contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | isavuconazole (Cresemba®) | ||
| Formulation | 100 mg capsule; 200 mg powder for concentrate for solution for infusion | ||
| Reference number | 2433 | ||
| Indication | Treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate |
||
| Company | Basilea Pharmaceuticals Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 3616 | ||
| NMG meeting date | 02/11/2016 | ||
| AWMSG meeting date | 07/12/2016 | ||
| Ratification by Welsh Government | 22/12/2016 | ||
| Date of issue | 04/01/2017 | ||
| Date of last review | September 2020 | ||
| Commercial arrangement | WPAS | ||